Scienza e Tecnologia
Lesaffre acquires Recombia Biosciences, a biotechnology company specialized in high-throughput genome editing and synthetic biology
Recombia Biosciences will be docked to the Lesaffre Bioengineering Center of Excellence, a major department of the Lesaffre Institute of Science and Technology, the company's corporate R&D entity made of almost 200 very passionate, international researchers.
For Lesaffre, the acquisition of Recombia Biosciences is part of a comprehensive strategy to invest heavily in research and development to unlock the full potential of micro-organisms, such as yeast or beneficial bacteria.
says Brice-Audren Riché, Lesaffre's CEO.
Recombia Biosciences will keep its name and will continue to grow dynamically at its location in Brisbane, California . At this stage, Recombia Biosciences' main mission will be to exploit its high-throughput genome editing and synthetic biology technologies to benefit the diverse businesses of Lesaffre. The future direction of Recombia's scientific and technology programs will be jointly defined by a specific Lesaffre-Recombia Board chaired by Recombia cofounder Lars Steinmetz .
Founded by Justin Smith ,
Bob St.Onge and Lars Steinmetz , Recombia Biosciences licensed its core technologies from
Stanford University . These technologies are unique and based on techniques that increase the efficiency of genome editing and enable very high-throughput strain engineering.
Photo - https://mma.prnewswire.com/media/1893480/Lesaffre_Recombia_Biosciences_1.jpg
Photo - https://mma.prnewswire.com/media/1893481/Lesaffre_Recombia_Biosciences_2.jpg
Photo - https://mma.prnewswire.com/media/1893482/Lesaffre_Recombia_Biosciences_3.jpg
Logo - https://mma.prnewswire.com/media/1893479/Lesaffre_Logo.jpg
PDF - https://mma.prnewswire.com/media/1893483/Lesaffre_Recombia_Biosciences.pdf
Jean-Clément Vergeau
j.vergeau@Lesaffre.com
Sandrine Verre
s.verre@lesaffre.com